{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:56:51Z","timestamp":1769025411597,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.ijom.2007.04.003","type":"journal-article","created":{"date-parts":[[2007,6,14]],"date-time":"2007-06-14T05:04:48Z","timestamp":1181797488000},"page":"632-639","source":"Crossref","is-referenced-by-count":27,"title":["Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"M.A.","family":"Scheper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.G.","family":"Nikitakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Sauk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijom.2007.04.003_bib1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2002-07-2130","article-title":"Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma","volume":"101","author":"Aoki","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ijom.2007.04.003_bib2","first-page":"945","article-title":"Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention","volume":"8","author":"Buettner","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijom.2007.04.003_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1073\/pnas.95.2.681","article-title":"Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis","volume":"95","author":"Chan","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijom.2007.04.003_bib4","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/ijc.22153","article-title":"What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis?","volume":"119","author":"Furstenberger","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijom.2007.04.003_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/A:1005924730450","article-title":"Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines","volume":"48","author":"Han","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ijom.2007.04.003_bib6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0006-2952(96)00181-5","article-title":"Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway","volume":"52","author":"Hanif","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ijom.2007.04.003_bib7","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/sj.onc.1202085","article-title":"Sulindac sulfide inhibits Ras signaling","volume":"17","author":"Herrmann","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.ijom.2007.04.003_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer statistics 2004","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijom.2007.04.003_bib9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/00001813-200507000-00002","article-title":"Targeting Stat3 in cancer therapy","volume":"16","author":"Jing","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ijom.2007.04.003_bib10","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1038\/sj.onc.1207606","article-title":"STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells","volume":"23","author":"Kanda","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ijom.2007.04.003_bib11","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ijom.2007.04.003_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/jcp.10327","article-title":"Survivin study: what is the next wave?","volume":"197","author":"Li","year":"2003","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ijom.2007.04.003_bib13","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1038\/sj.bjc.6601402","article-title":"Survivin expression in oral squamous cell carcinoma","volume":"89","author":"Lo Muzio","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijom.2007.04.003_bib14","first-page":"1004","article-title":"The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells","volume":"62","author":"Nikitakis","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijom.2007.04.003_bib15","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ijc.10278","article-title":"PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells","volume":"98","author":"Nikitakis","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijom.2007.04.003_bib16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2174\/1568009043332736","article-title":"Targeting the STAT pathway in head and neck cancer: recent advances and future prospects","volume":"4","author":"Nikitakis","year":"2004","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.ijom.2007.04.003_bib17","first-page":"2452","article-title":"Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction","volume":"57","author":"Piazza","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijom.2007.04.003_bib18","first-page":"2085","article-title":"Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines","volume":"60","author":"Rahman","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijom.2007.04.003_bib19","first-page":"4103","article-title":"COX-independent antineoplastic effects of sulindac in oral cancer are mediated by survivin downregulation","volume":"26","author":"Scheper","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijom.2007.04.003_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI118060","article-title":"Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells","volume":"96","author":"Shiff","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijom.2007.04.003_bib21","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/sj.bjc.6602055","article-title":"Abrogation of IL-6-mediated JAK signalling by the cyclopentenone prostaglandin 15d-PGJ(2) in oral squamous carcinoma cells","volume":"91","author":"Siavash","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijom.2007.04.003_bib22","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/sj.onc.1203483","article-title":"STAT signaling in head and neck cancer","volume":"19","author":"Song","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.ijom.2007.04.003_bib23","first-page":"2948","article-title":"Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine\/paracrine stimulation of the interleukin 6\/gp130 cytokine system","volume":"63","author":"Sriuranpong","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijom.2007.04.003_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0165-6147(02)00043-3","article-title":"Cyclooxygenase 2: a molecular target for cancer prevention and treatment","volume":"24","author":"Subbaramaiah","year":"2003","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ijom.2007.04.003_bib25","doi-asserted-by":"crossref","first-page":"27307","DOI":"10.1074\/jbc.274.38.27307","article-title":"Sulindac inhibits activation of the NF-kappaB pathway","volume":"274","author":"Yamamoto","year":"1999","journal-title":"J Biol Chem"}],"container-title":["International Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0901502707001671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0901502707001671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T02:18:56Z","timestamp":1556504336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0901502707001671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0901502707001671"],"URL":"https:\/\/doi.org\/10.1016\/j.ijom.2007.04.003","relation":{},"ISSN":["0901-5027"],"issn-type":[{"value":"0901-5027","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}